TFF Pharmaceuticals Congratulates Scientific Advisory Board Member Drew Weissman for Receiving Nobel Prize in Physiology or Medicine for Pioneering Work on mRNA COVID-19 Vaccines

Drew Weissman, M.D., Ph.D., a member of TFF Pharmaceuticals' Scientific Advisory Board, receives Nobel Prize for his work on mRNA COVID-19 vaccines.

Congratulations to Dr. Drew Weissman, a member of TFF Pharmaceuticals' Scientific Advisory Board, for being awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work in enabling the development of mRNA COVID-19 vaccines. TFF Pharmaceuticals, a clinical-stage biopharmaceutical company, is focused on developing and commercializing innovative drug products using its patented Thin Film Freezing technology platform.

Dr. Weissman, a physician-scientist and immunology expert, holds the Roberts Family Professorship in Vaccine Research at the University of Pennsylvania's Perelman School of Medicine. His research on ribonucleic acids (RNA) and the innate immune system has greatly contributed to the field of immunology. Notably, his collaboration with Dr. Katalin Karikó led to advancements in messenger RNA (mRNA) biology, which played a crucial role in the development of the first FDA-approved mRNA vaccines for COVID-19.

Continuing his research, Dr. Weissman and his team are exploring the potential of nucleoside-modified mRNA in developing safe and effective vaccines and therapeutics for various diseases. He has published extensively on vaccines for infectious diseases such as flu, herpes, and HIV and has received numerous prestigious awards, including the NIH Merit Award, NIH Special Achievement Award, and the 50th Rosenstiel Award for Distinguished Work in Medical Science.

TFF Pharmaceuticals' Thin Film Freezing (TFF) technology is a proprietary particle engineering process that transforms both existing compounds and new chemical entities into dry powder formulations. These formulations offer unique advantages for inhalation, as well as other routes of administration such as parenteral, nasal, oral, topical, and ocular. By delivering therapies directly to the target organ, such as the lung, TFF powders can be administered at lower doses compared to oral drugs, reducing unwanted side effects. Laboratory data suggests that TFF powders can deliver up to 75% of the dose to the deep lung. Importantly, the TFF process does not compromise the integrity of delicate therapeutic components, making it suitable for reformulating fragile biologics into temperature-stable dry powders.

TFF Pharmaceuticals is committed to leveraging its TFF technology platform to develop potent dry powder formulations that enhance the efficacy, safety, and stability of medicines. The company's lead drug candidates, TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder), are currently in clinical trials. Through collaborations with pharmaceutical companies, academic institutions, and government partners, TFF Pharmaceuticals aims to revolutionize healthcare worldwide. The TFF Platform is protected by over 120 patents issued or pending in the U.S. and internationally.

For more information about TFF Pharmaceuticals and its product candidates, please visit their official website at https://tffpharma.com.

Share With Others